Paper26769332
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.
Bissonnette R and 10 others. J Dermatolog Treat, 2016. Cited by 66 papers, by iCite.
Cite this record
ConductScience Library. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. Papers, record 26769332. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26769332
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Azetidines | Major topic |
| Isonicotinic Acids | Major topic |
| Psoriasis | Major topic |
| Adult | |
| Aged | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Janus Kinase 1 | |
| Male | |
| Middle Aged | |
| Treatment Outcome |
Source PubMed
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 66 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42396462 | JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases. | Front Immunol | 2026 | https://conductscience.org/library/papers/42396462 | PubMed |
| 42187316 | Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients. | J Eur Acad Dermatol Venereol | 2026 | https://conductscience.org/library/papers/42187316 | PubMed |
| 39995941 | Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022. | Heliyon | 2025 | https://conductscience.org/library/papers/39995941 | PubMed |
| 39367521 | Infection risk with JAK inhibitors in dermatoses: a meta-analysis. | Int J Dermatol | 2025 | https://conductscience.org/library/papers/39367521 | PubMed |
| 39283290 | Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL). | Future Oncol | 2024 | https://conductscience.org/library/papers/39283290 | PubMed |
| 39119317 | Small Molecules in the Management of Psoriasis and Psoriatic Arthritis. | Indian J Dermatol | 2024 | https://conductscience.org/library/papers/39119317 | PubMed |
| 38892802 | Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition. | J Clin Med | 2024 | https://conductscience.org/library/papers/38892802 | PubMed |
| 38731900 | Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38731900 | PubMed |
| 38444845 | Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses. | Front Immunol | 2024 | https://conductscience.org/library/papers/38444845 | PubMed |
| 38399292 | New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38399292 | PubMed |
| 38314280 | Janus kinase inhibitors modify the fatty acid profile of extracellular vesicles and modulate the immune response. | Heliyon | 2024 | https://conductscience.org/library/papers/38314280 | PubMed |
| 37927384 | JAK Inhibitors in Psoriatic Disease. | Clin Cosmet Investig Dermatol | 2023 | https://conductscience.org/library/papers/37927384 | PubMed |
| 37784164 | Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy. | Cell Commun Signal | 2023 | https://conductscience.org/library/papers/37784164 | PubMed |
| 37123059 | Recent advances in targeted therapy for pancreatic adenocarcinoma. | World J Gastrointest Oncol | 2023 | https://conductscience.org/library/papers/37123059 | PubMed |
| 36163193 | Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. | BMC Rheumatol | 2022 | https://conductscience.org/library/papers/36163193 | PubMed |
| 35265634 | Novel Therapeutic Target(s) for Psoriatic Disease. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35265634 | PubMed |
| 35096256 | Review on Novel Oral Therapies for Psoriasis. | J Clin Aesthet Dermatol | 2021 | https://conductscience.org/library/papers/35096256 | PubMed |
| 34848210 | The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. | J Allergy Clin Immunol | 2022 | https://conductscience.org/library/papers/34848210 | PubMed |
| 34640327 | Role of Janus Kinase Inhibitors in Therapy of Psoriasis. | J Clin Med | 2021 | https://conductscience.org/library/papers/34640327 | PubMed |
| 34073410 | Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies? | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34073410 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| JAK1 | 3716 | PubTator's text mining | https://conductscience.org/library/genes/3716 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26769332
GET https://conductscience.org/api/papers/v1/26769332/cited_by?page=2